Icon

Quillivant XR - (5 mg/mL; Extended-release Oral Suspension)

Methylphenidate Hydrochloride Tris pharma
5 mg/mL; Extended-release Oral Suspension
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
None None
Indicated for the treatment of Attention Deficit Hyperactivity Disorder
Yes
******* ** *** ***** ** **** **** ** **** ******* '*** (***** **, ****); '***, '***, '***, , '***, '***, '*** *** ******** ** *** **, **** *** *** ************ *********. ******* *** ****** **** ***** **** ** **** **** ******* ** ******* *** *** *********. ********** **** ******* *********, ********** **** *** ** ********* ***** *** ***** ** ********* *** *** *****. ******* *** ** '***, '***, *** '*** ** ** **** ****. *****, **** **** ** *********** ** ** *** ********* ** ******* ** **** ** **** *******. *** **** *** ******** *** *** ****** ***** ********* **** ** ****** ** **** ******. ******* ****** ****** ****** *** **, **** ** ********* ** ***** *********.
Quillivant XR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7
******* *** ********* *** ********* **** ** ** **** ** ** **** ** ** *** ********* *** *********
*** ****** ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ********* ***** **, **** **** ** ** **** ***** *** **, ****
*** ****** *** \ ********* **** **, **** ******* **** ***** *** **, ****
  1. *** *, **** : ******* ******** **** ***** *** **** ** **** ******* '***, '***, '***, '***, '***.
  2. *** **, **** : **** ***** * **** ******* ******* ** ******** ***** ** ** *** ******** ***** ** ********.
  3. *** **, **** : **** ****** ***** * **** ******* *** ** *** ***** **** ** **** ******* '***, '***, '***, '***, '***, '***, '***.
  4. *** **, **** : **** ***** * **** ******* ******* ** ******** ***** ** ******** ** ******* ***** **** ** **** ****** '***.
  5. *** **, **** : **** ***** * **** ******* ******* ** ******** ***** ** ******** ** ******* ***** **** ** **** ****** '***.
  6. *** *, **** : ********** *** ********* **** *** ***** *** ***** ** ********* *** *** *****.
  7. *** *, **** : ******* **** ** ****** **. '*** '*** *** '*** .

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.